Science Corporation just cleared a significant hurdle on its path to transforming healthcare technology. The company’s PRIMA retinal implant system has received the CE mark approval under the EU Medical Device Regulation. This not only means Science Corp can commercialize its system across more than 30 European countries, but it also reaffirms their technological prowess in the field of brain-computer interfaces (BCI).
Max Hodak, Science Corp’s CEO and former Neuralink co-founder, has been vocal about the crucial successes needed in this fledgling space. According to Hodak, companies should aim to generate $100 million in annual revenue to truly demonstrate their viability. With this approval, Science Corp is positioning itself to meet and possibly exceed these expectations, marking a potential paradigm shift in how severe vision impairments are treated.
The Details
The PRIMA implant, born out of research from Stanford University, uses wireless photovoltaic technology to help restore central vision in patients with geographic atrophy due to age-related macular degeneration (AMD). Paired with specialized glasses, it acts like a window into the future of visual aids. Imagine having a bionic eye that taps into your brain signals—that’s where we’re headed.
